A nderson-Fabry disease (AFD) is an X-linked disorder of lysosomal metabolism characterized by progressive accumulation of intralysosomal sphingolipids in multiple organs (1). Cardiac involvement in AFD can result in left ventricular hypertrophy (LVH), myocardial fibrosis, heart failure, and arrhythmia (2,3). Patients with AFD can be treated with enzyme replacement therapy, which should be initiated before irreversible cardiac changes occur (4). Therefore, timely diagnosis and monitoring of AFD are imperative. However, differentiation of AFD from other causes of LVH such as hypertrophic cardiomyopathy (HCM) remains a clinical challenge, given overlap in imaging findings (5).
A nderson-Fabry disease (AFD) is an X-linked disorder of lysosomal metabolism characterized by progressive accumulation of intralysosomal sphingolipids in multiple organs (1) . Cardiac involvement in AFD can result in left ventricular hypertrophy (LVH), myocardial fibrosis, heart failure, and arrhythmia (2, 3) . Patients with AFD can be treated with enzyme replacement therapy, which should be initiated before irreversible cardiac changes occur (4) . Therefore, timely diagnosis and monitoring of AFD are imperative. However, differentiation of AFD from other causes of LVH such as hypertrophic cardiomyopathy (HCM) remains a clinical challenge, given overlap in imaging findings (5) .
Cardiac magnetic resonance (MR) imaging T1 mapping is useful in characterization of myocardial tissue. Cardiac MR imaging native left ventricular (LV) T1 values at 1.5 T are lower in patients with AFD compared with those in healthy volunteers and in patients with LVH from other causes (6) (7) (8) (9) . However, to our knowledge, cardiac MR imaging T1 mapping at 3.0 T has not been previously reported in patients with AFD. Furthermore, only one small study has reported reduced right ventricular (RV) native T1 values in AFD compared with pulmonary hypertension (9) .
The purpose of our study was to compare LV and RV 3.0-T cardiac MR imaging T1 values in AFD and HCM and to evaluate the diagnostic value of native T1 values beyond age, sex, and conventional imaging features. We hypothesized that native T1 values would be significantly lower in AFD compared with HCM and would provide incremental diagnostic value beyond age, sex, and conventional imaging features.
Materials and Methods

Study Population
Our prospective study was approved by our institutional research and ethics board. Data collection was planned Use of Myocardial T1 Mapping at 3.0 T to Differentiate Anderson-Fabry Disease from Hypertrophic Cardiomyopathy prior to initiation of the study. Between June 2016 and September 2017, a convenience sample of patients with AFD and HCM referred for 3.0-T cardiac MR imaging as part of the clinical management protocol were prospectively recruited for T1 mapping (Fig 1) . Written informed consent was obtained from all study participants. Exclusion criteria included prior myocardial infarction, known severe coronary artery disease, or contraindications to MR imaging and imaging at 1.5 T. The final cohort consisted of 30 patients with gene-positive AFD with mean age 6 standard deviation of 45.0 years 6 14.1 ( (10) . Clinical and demographic data were obtained from the electronic patient record.
Cardiac MR Imaging Technique
Cardiac MR imaging was performed with a 3.0-T imager (Magnetom Skyra Fit; Siemens Healthcare, Erlangen, Germany). Retrospectively gated cine steady-state free precession images were obtained in multiple planes. Frequency scouting and adjustment were used for steady-state free precession imaging. LV and RV volumes, function, and mass were assessed by using a stack of short-axis cine steady-state free precession sections with coverage from cardiac base to the apex (repetition time msec/echo time msec, 40/1.19; field of view, 360 mm; section thickness, 8 mm; intersection gap, 2 mm). T1 mapping was performed with a steady-state free precession readout modified Look-Locker inversion recovery (MOLLI) acquisition scheme by using recommended MOLLI inversion groupings (before administration of contrast material, 5 [3] 3; after administration of contrast material, 4[1]3 [1] 2) (typical imaging parameters: 280/1.12; field of view, 360 mm; section thickness, 8 mm). Three short-axis sections were acquired at the base, midventricle, and apex before and 12-15 minutes after administration of 0.15 mmol/kg body weight of gadobutrol (Gadovist; Bayer Healthcare, Berlin, Germany) (11) . Multiplane late gadolinium enhancement (LGE) imaging was performed approximately 15 minutes after administration of contrast agent, with a phase-sensitive inversion recovery gradient-recalled echo sequence (781/1.97; field of view, 360 mm; section thickness, 8 mm; intersection gap, 2 mm).
Cardiac MR Imaging Postprocessing
All cardiac MR imaging analyses were performed by a fellowship-trained radiologist (G.R.K., with 3 years of cardiovascular imaging experience) blinded to all identifying information including clinical diagnosis. Quantification of LV and RV volumes, function, and mass was performed with commercially available software (QMass, Medis Suite version 3.0.18.6; Medis Medical Imaging Systems, Leiden, the Netherlands). LVH was defined as LV mass indexed to body surface area above 85 g/m 2 in men and above 81 g/m 2 in women (12) . RV hypertrophy was defined as RV mass indexed to body surface area above 29 g/m 2 in men and above 28 g/m 2 in women (12) . Maximum end-diastolic LV and RV wall thicknesses were measured on short-axis cine steady-state free precession images. The presence of accessory apical-basal muscle bundles and myocardial crypts, which are considered characteristic imaging features in HCM, was evaluated on cine steady-state free precession images. An apical-basal muscle bundle was defined as a muscle band extending from LV apex to basal septal or anterior segments without chordal attachment to the mitral valve (13) 
Implications for Patient Care
n Cardiac MR imaging native T1 mapping at 3.0 T distinguishes Anderson-Fabry disease (AFD) from hypertrophic cardiomyopathy (HCM) without the need for administration of contrast agent.
n Septal left ventricular native T1 values have independent and incremental value over age, sex, and conventional imaging features to differentiate AFD from HCM.
n A septal left ventricular native T1 cutoff point of 1220 msec or lower at 3.0 T distinguishes AFD from HCM with high sensitivity, specificity, and accuracy. myocardial crypt was defined as a focal myocardial defect with a depth of 50% or greater than the myocardium adjacent to it (14) .
LGE images were assessed for the presence of any LGE,
LGE excluding RV insertion points, and LGE at the basal inferior-lateral myocardium. Basal inferior-lateral LGE is considered a characteristic imaging feature in AFD (5). Inline, nonrigid motion correction of individual T1 mapping images was performed. Offline T1 mapping analysis was performed with commercially available software (cmr42, version 5.6.3; Circle Cardiovascular Imaging, Calgary, Canada). For assessment of global LV T1 values, the LV epicardium and endocardium were contoured at basal, midventricular, and apical sections, with care taken to avoid blood pool and epicardial fat; T1 values were averaged across the three sections (Figs 2, 3). Septal LV T1 values were evaluated by drawing a single region of interest on the midventricular section in the midinterventricular septum, avoiding the anterior and inferior RV insertion points, and ensuring a minimum regionof-interest size of 1.5 cm 2 (15) (16) (17) . For assessment of RV T1 values, a single region of interest was drawn in the lateral or inferior RV wall, ensuring a minimum region-of-interest size of 0.15 cm 2 (18) . If a region of interest could not be reliably drawn within the RV myocardium meeting this criterion, then RV T1 values were excluded in that subject (16 of 60 [27%] ). Areas with LGE were not excluded from T1 analysis. LV (global and septal) and RV myocardial extracellular volume (ECV) values were calculated with input of native and postcontrast myocardial and blood pool T1 values and hematocrit as described by Arheden et al (19) .
Intraobserver and Interobserver Agreement
To assess intraobserver agreement, a random subset of 20 studies was reanalyzed by the same reader following a minimum 2-week interval after the first analysis; the reader was blinded to the results of the initial assessment and all identifying data. To assess interobserver agreement, the same subset was analyzed by a second experienced fellowship-trained reader (K.H., with 5 years of cardiovascular imaging experience) who was blinded to all identifying information, including the results of the initial assessment.
Statistical Analysis
Statistical analysis was performed with software (Stata, version 14.1; Stata, College Station, Tex). Two-tailed P , .05 . Septal left ventricular (LV) native T1 findings were assessed by drawing region of interest (black arrowhead) in interventricular septum. Global LV native T1 findings were assessed by drawing epicardial (black arrows) and endocardial (white arrows) contours in LV myocardium. Right ventricular (RV) native T1 findings were assessed by drawing region of interest in RV lateral or free wall (white arrowheads). Areas with LGE (yellow arrow) were not excluded from T1 analysis. Septal LV, global LV, and RV native T1 findings are 1113 msec, 1173 msec, and 1234 msec in male subject and 1167 msec, 1263 msec, and 1237 msec in female subject, respectively. Native T1 and ECV Findings Septal LV native T1 values did not differ significantly between patients with AFD who were treated with enzyme replacement therapy and those who were not (1160 msec 6 38 vs 1161 msec 6 51, respectively; P = .92). Among patients with AFD, septal LV native T1 values did not differ significantly between men and women (1150 msec 6 54 vs 1167 msec 6 42, respectively; P = .36) or between patients with LVH and those without LVH (1156 msec 6 26 vs 1162 msec 6 49, respectively; P = .83).
RV native T1 values correlated positively with global (r = 0.480; P = .001) and septal (r = 0.392; P , .001) LV native T1 values, respectively. Among patients with AFD, RV native T1 values were significantly higher compared with global (P = .01) and septal (P , .001) LV native T1 values. Global LV native T1 values were significantly higher compared with septal LV native T1 values (P , .001). Global LV ECV values were significantly higher compared with septal LV ECV values (P = .009).
Global LV, septal LV, and RV native T1 values were all significantly lower in AFD compared with HCM (P , .001, P , performed to evaluate the independent value of septal LV native T1 mapping in differentiation of AFD from HCM in a model with age, sex, and conventional imaging features (presence of basal inferolateral LGE, apical-basal muscle bundle, and myocardial crypt). For assessment of incremental diagnostic value, the likelihood ratio test was used to compare nested models with only age, sex, and conventional imaging features versus one with septal LV native T1 values added. Receiver operating characteristic curves were created to evaluate the ability of native T1 values to discriminate between groups. Areas under the receiver operating characteristic curve (AUC) for native T1 values were tested for equality (20) . The optimal LV native T1 value threshold for distinguishing AFD from HCM was identified, maximizing accuracy. Intraobserver agreement and interobserver agreement were assessed with individual intraclass correlation coefficient with one-way random-effects models and two-way random-effects models, respectively.
Results
Study Population
Demographic information is summarized in Table 1 . Ten patients with AFD (10 of 30 [33%]) were treated with enzyme replacement therapy at the time of cardiac MR imaging. AFD and HCM groups did not differ significantly with regard to age (P = .24) or sex (P = .20). There was no significant difference in age between men and women in either the AFD group (P = .64) or the HCM group (P = .38).
Cardiac MR Imaging Findings
Cardiac MR imaging findings are summarized in Table 2 . Maximum LV wall thickness was significantly higher in HCM compared with AFD (P , .001). However, there was no significant difference in maximum RV wall thickness (P = . 16 
Discussion
Differentiation of AFD from HCM remains a clinical challenge, given overlap in imaging findings (5) . Confirming results of 1.5-T imaging, our findings show that LV and RV native T1 values are significantly lower in patients with AFD compared with HCM at 3.0 T. In addition, we found that septal native LV T1 values have independent and incremental value over age, sex, and conventional imaging features (presence of basal inferolateral LGE, apical-basal muscle bundle, and myocardial crypt) in differentiating AFD from HCM. A septal native LV T1 cutoff point of 1220 msec or lower with use of a MOLLI sequence at 3.0 T distinguishes AFD from HCM with high sensitivity and specificity.
Only a few prior studies have reported LV T1 values in patients with AFD imaged at 1.5-T (6-9). Two prior studies reported that native T1 values obtained with shortened MOLLI and saturation recovery single-shot acquisition schemes at 1.5 T were lower in patients with AFD than in healthy control participants and patients with other causes of LVH (6,7). Notably, previous publications have not evaluated native myocardial T1 values at 3.0 T in AFD. Consistent with the findings of other studies, our study demonstrates that native RV T1 values are higher compared with native LV T1 values (21) . Native RV T1 values correlate positively with LV T1 values, suggesting common biventricular pathologic features (9) . However, RV T1 values have lower intraobserver and interobserver reproducibility compared with LV T1 values. Global LV native T1 and ECV values are significantly higher compared with septal LV native .001, and P = .001, respectively) (Fig 4a) . Global LV (P = .95), septal LV (P = .12), and RV (P = .22) ECV values did not differ significantly between AFD and HCM (Fig 4b) .
The AUC to discriminate AFD from HCM was significantly higher for septal Univariable logistic regression results are presented in Table 3 . In a multivariable logistic regression model, septal LV native T1 values differentiate AFD from HCM with age, sex, and conventional imaging features controlled for (odds ratio, 0.94; 95% CI: 0.91, 0.98; P , .001). In a nested logistic regression model with age, sex, and conventional imaging features, model fit is significantly improved by the addition of LV native T1 values (x 2 [df = 1] = 33.4; P , .001).
Intraobserver and Interobserver Agreement
Intraobserver agreement and interobserver agreement were good to excellent for septal and global LV T1 and ECV values, but moderate to poor for RV T1 and ECV values (Table 4) . (27) .78 Calcium channel blockers 1 (3) 3 (10) .61 ACEIs/ARBs 9 (30) 2 (7) .04
Note.-Unless otherwise indicated, data are means 6 standard deviation. ACEI = angiotensin converting enzyme inhibitor, ARB = angiotensin II receptor blocker.
* Data are the number of patients, with percentage in parentheses.
LV septal T1 value of 940 msec or lower with use of a shortened MOLLI sequence (without exclusion of areas of LGE) could be used to distinguish AFD from non-AFD causes of LVH. Thompson et al (6) reported that native LV global T1 cutoff points of 1146 msec or lower in women and 1120 msec or lower in men with use of a saturation recovery single-shot acquisition sequence allowed differentiation of patients with AFD from healthy control participants and patients with LVH from other causes. Native T1 values are higher at 3.0 T compared with 1.5 T because of the difference in magnetic field strength, which explains the higher cutoff point for AFD identified at 3.0-T imaging in our study (22, 23) .
T1 and ECV values, respectively, likely because of the absence of replacement fibrosis in the septum in patients with AFD (7). Although global LV native T1 values had slightly better reproducibility compared with septal LV native T1 values, septal LV native T1 values are recommended in the setting of patients suspected of having AFD, given better discrimination and ease of measurement. Although RV native T1 values are also reduced in AFD, RV native T1 assessment is not recommended for clinical use, given poor reproducibility. Two prior studies in which 1.5-T imaging was used reported slightly lower native T1 cutoff points for AFD compared with the results from our study. Sado et al (7) reported that a native There was no significant difference in ECV values between groups, consistent with the results of a prior study performed at 1.5 T (6) . ECV values may be within the normal range in AFD because AFD is an intracellular (lysosomal) storage disorder (24) . Although patients with HCM may have slightly higher ECV values compared to healthy volunteers as a result of diffuse interstitial fibrosis, ECV values can be within the upper range of normal, particularly when calculated from segments without LGE (24, 25) .
Distinguishing among different potential causes of LVH is a clinical and imaging challenge. Native cardiac MR imaging T1 values at both 1.5 T and 3.0 T are reduced in AFD compared with other causes of LVH; therefore, this imaging biomarker could be instrumental in the early identification of cardiac involvement in patients with AFD. Multiple reports have stressed the role of early treatment and disease monitoring with cardiac MR imaging in patients with AFD (26) (27) (28) . Renal impairment affects a substantial proportion of patients with AFD; end-stage renal disease was reported in 17% of men and 1% of women in a large cohort (29, 30) . In this setting, administration of gadoliniumbased contrast material can be avoided with use of native myocardial T1 mapping for characterization of myocardial tissue. However, this remains to be evaluated in a separate study including participants with renal impairment. It is important to note that native T1 values are also shortened in the setting of fat and iron overload, although the clinical presentation typically differs (31) . There were several limitations of this study. AFD is a relatively rare condition, thus limiting the number of participants. Imaging was performed with a single MR imager and T1 mapping sequence, and therefore results may not be generalizable to all centers. Some of the patients with AFD included in our study were undergoing treatment with enzyme replacement therapy at the time of cardiac MR imaging, which could have affected T1 values. The diagnostic performance values for the cutoff point identified in our study are likely optimistic because they are derived from the same data that generated the model. Although care was taken to draw regions of interest in the RV myocardium, partial volume averaging and contamination of T1 values from the inadvertent inclusion of blood pool or epicardial fat are potential pitfalls that could result in artificially high RV native T1 and ECV values.
In conclusion, cardiac MR imaging native T1 values at 3.0 T are significantly lower in patients with AFD compared with HCM and provide independent and incremental diagnostic value beyond age, sex, and conventional imaging features.
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